Purpose Healthcare Innovation Yield A (PFC5200)
19.89
+0.42 (+2.14%)
CAD |
Jul 05 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| -- | 2.668M | 0.00% | -- |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -- | -- | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The fund’s investment objective is to provide unitholders with exposure to biotechnology and healthcare companies with: (i) the opportunity for capital appreciation; (ii) monthly cash distributions; and (iii) lower volatility of investment portfolio returns when compared to owning the underlying securities of the fund directly. Investments by the fund may be made globally. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | -- |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Purpose Investments Inc. |
| Prospectus Benchmark Index | |
| N/A | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Vlad Tasevski | 0.37 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
--
-391.33M
Category Low
445.62M
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of June 30, 2022
Performance Versus Category
As of July 05, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of July 05, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Johnson & Johnson | 4.33% | 178.14 | 0.00% |
| Pfizer Inc | 4.10% | 52.40 | 1.47% |
| Regeneron Pharmaceuticals Inc | 3.69% | 600.33 | 0.63% |
| Thermo Fisher Scientific Inc | 3.43% | 547.52 | 0.45% |
| Eli Lilly and Co | 3.41% | 328.96 | 0.54% |
| Abbott Laboratories | 3.40% | 108.32 | -0.90% |
| Merck & Co Inc | 3.11% | 94.15 | 1.63% |
| UnitedHealth Group Inc | 3.00% | 511.53 | 1.24% |
| Amgen Inc | 2.79% | 246.57 | -0.06% |
| Zoetis Inc Class A | 2.48% | 176.70 | 1.41% |
Basic Info
| Investment Strategy | |
| The fund’s investment objective is to provide unitholders with exposure to biotechnology and healthcare companies with: (i) the opportunity for capital appreciation; (ii) monthly cash distributions; and (iii) lower volatility of investment portfolio returns when compared to owning the underlying securities of the fund directly. Investments by the fund may be made globally. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | -- |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | -- |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Purpose Investments Inc. |
| Prospectus Benchmark Index | |
| N/A | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Vlad Tasevski | 0.37 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (7-5-22) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield (5-26-22) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 20.67 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of May 31, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 1/18/2022 |
| Last Annual Report Date | 12/31/2021 |
| Last Prospectus Date | -- |
| Share Classes | |
| PFC5201 | Fee-based Advice |
| PFC5202 | Institutional |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |